Complete your personal information for a more tailored experience
Home
Don't miss out
Subscribe to STAT+ today, for the best life sciences journalism in the industry
By Katie Palmer
Jan. 6, 2025
Health Tech Correspondent
After nearly a decade of machine learning innovation in the drug industry, the U.S. Food and Drug Administration today published its first draft guidance on the use of artificial intelligence in the development of drugs and biological products.
The guidance comes as drug regulatory submissions citing AI have increased exponentially. In an interview with STAT in October, the FDA’s Tala Fakhouri, who co-leads the Center for Drug Evaluation and Research’s AI Council, said the agency has received over 500 drug submissions with AI components since 2016, with a large number in the areas of oncology, neurology, and gastroenterology.
advertisement
Industry members have described a shift in the last 18 months in regulatory bodies’ interest in how AI is used in drug development. The FDA’s new draft guidance comes on the heels of a reflection paper from the European Medicines Agency on the use of AI in the drug product lifecycle, finalized in September 2024. “Regulatory clarity is one of the top three barriers of adopting AI in this space,” said Xiaolan Wang, senior vice president of life sciences solutions at clinical data company IMO Health.
STAT+ Exclusive Story
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$20
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
Katie Palmer
Health Tech Correspondent
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses.
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
By Meghana Keshavan
By Adam Feuerstein
advertisement
By Meghana Keshavan
By Allison DeAngelis
By Lizzy Lawrence
By Lizzy Lawrence
By Mario Aguilar
By Bob Herman, Tara Bannow, Casey Ross, and Lizzy Lawrence
By John Wilkerson
By Jason Mast
Share options
X
Bluesky
LinkedIn
Facebook
Doximity
Copy link
Reprints
Reporting from the frontiers of health and medicine
Company
Account
More
